Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
Neurosterix, spun out from Addex Therapeutics, secures $105 million Series B to advance a schizophrenia candidate and recruits executives from Karuna Therapeutics' Cobenfy program.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Swiss biotech Neurosterix announced the close of a $105 million Series B financing round on November 12, 2026, according to coverage from Business Wire, GlobeNewswire, Yahoo Finance, BioSpace, Fierce Biotech, Endpoints News, Dealroom, and Startupticker.ch. The company, originally spun out from Addex Therapeutics, intends to use the proceeds to fund a Phase 2 clinical trial for its lead schizophrenia drug candidate. Coverage consistently identifies the financing as a Series B round valued at $105 million and notes the simultaneous appointment of senior executives with direct experience developing Karuna Therapeutics' Cobenfy (xanomeline-trospium), the first muscarinic agonist approved for schizophrenia. The press release distributed by Business Wire and syndicated across the other outlets names the new appointees as veterans of the Cobenfy development program, though specific titles and responsibilities vary slightly across the eight articles. Fierce Biotech and Endpoints News emphasize the strategic significance of recruiting talent from the only recently approved novel mechanism in schizophrenia, while BioSpace and Startupticker.ch highlight the company's stated mission to "transform neuropsychiatric care by fine-tuning brain signaling." Dealroom and Yahoo Finance frame the raise within the broader context of heightened investor interest in neuropsychiatry following Karuna's acquisition by Bristol Myers Squibb.
The coverage emphasizes two parallel tracks: capital deployment toward a Phase 2 readout and team construction around a validated mechanism. Business Wire's release provides the most detailed corporate statement, quoting Neurosterix leadership on the rationale for targeting muscarinic pathways and the advantage of hiring developers who have already navigated regulatory approval for a first-in-class schizophrenia therapy. Fierce Biotech and Endpoints News both note that the $105 million figure positions Neurosterix among the larger Series B rounds in European CNS biotech this year. GlobeNewswire and Yahoo Finance reproduce the same release text with minimal editorial framing, while Dealroom categorizes the deal under "neuropsychiatry" and "orphan drugs" tags.
Background context from the coverage indicates Neurosterix originated as a spin-out from Addex Therapeutics, a Swiss clinical-stage company specializing in allosteric modulation. The financing arrives amid a surge in schizophrenia drug development after decades of mechanistic stagnation. Neurosterix's recruitment of Cobenfy veterans signals an attempt to replicate that development playbook. Coverage does not specify the identity of other Series B investors beyond the aggregate amount, nor does it disclose Neurosterix's valuation, cash runway, or the exact timeline for Phase 2 initiation.
What to watch next based on stated facts: the initiation and design of the Phase 2 schizophrenia trial, including patient population, endpoints, and expected readout timing; further disclosure of the lead candidate's mechanism, preclinical data, and differentiation from existing muscarinic therapies; the integration and specific roles of the recruited Karuna veterans in clinical development and regulatory strategy; potential partnerships or additional financing as the program advances toward later-stage trials; and any regulatory interactions that may inform the development path given the novel mechanism. Coverage does not yet specify trial sites, comparator arms, or whether the company plans to pursue additional indications beyond schizophrenia.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (84% supported) Updated 4d ago.
Quick answers
How much did Neurosterix raise and what round is it?
Neurosterix closed a $105 million Series B financing round announced on November 12, 2026.
Who are the key hires and where did they come from?
The company appointed executives with experience developing Karuna Therapeutics' Cobenfy (xanomeline-trospium), the first muscarinic agonist approved for schizophrenia.
What will the funding be used for?
Proceeds are intended to fund a Phase 2 clinical trial for Neurosterix's lead schizophrenia drug candidate.
Coverage (8)
- Addex Spin-out Neurosterix Closes $105 Million Series B Financing Yahoo Finance · 5d ago
- Addex Spin-out Neurosterix Closes $105 Million Series B Financing GlobeNewswire · 5d ago
- Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push BioSpace · 5d ago
- Neurosterix lands $105M Series B for schizophrenia drug Dealroom · 5d ago
- Neurosterix Announces $105 Million Series B Financing and Appointments of Leading Neuropsychiatry Drug Development Executives Business Wire · 5d ago
- $105 Million to transform neuropsychiatric care by fine-tuning brain signaling Startupticker.ch · 5d ago
- Addex spinout Neurosterix raises $105M series B to fund phase 2 schizophrenia trial Fierce Biotech · 5d ago
- Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets Endpoints News · 5d ago
Topics
Related trends
A Gene Inherited From Neanderthals Is Still Shaping Human Brains
New research reveals a Neanderthal-inherited gene variant still reshapes modern human brains, shrinking the occipital lobe while cutting schizophrenia risk.
Seattle scientists help unveil ‘landmark’ findings on human brain
Seattle scientists help unveil landmark findings on the human brain, including a new cell map and a neuron potentially tied to schizophrenia.
Imaging study reveals widespread brain connection loss in schizophrenia
New imaging research utilizing SPECT and PET scans demonstrates widespread brain connection loss and receptor deficits in patients with schizophrenia.
A Gene Inherited From Neanderthals Is Still Shaping Human Brains
Recent coverage details how a specific DNA fragment inherited from Neanderthals protects against schizophrenia.
Ultrasound waves that jiggle deep brain structures may relieve delusions in schizophrenia, small trial hints
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
MapLight shares sink on mixed ph. 2 schizophrenia readout
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.